KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition Session Date and Time: Friday, ...
LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces the launch by its Rex MD men’s health brand of TestoRx, a new direct-to-consumer men’s hormone therapy ...